Therefore, simultaneous inhibition of the EGFR/MEK/ERK pathway and disruption of the PLK1-STAT3 axis effectively enhance antitumor efficacy and delay the development of acquired resistance in EGFR-mutant NSCLC. This evidence concerns the gene PLK1 and non-small cell lung carcinoma.